Novavax (Novavax) Days Sales Outstanding

: 75.78 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Novavax's average Accounts Receivable for the three months ended in Dec. 2023 was $210.4 Mil. Novavax's Revenue for the three months ended in Dec. 2023 was $253.4 Mil. Hence, Novavax's Days Sales Outstanding for the three months ended in Dec. 2023 was 75.78.

The historical rank and industry rank for Novavax's Days Sales Outstanding or its related term are showing as below:

NVAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.49 Med: 92.93 Max: 2196.98
Current: 106.43

During the past 13 years, Novavax's highest Days Sales Outstanding was 2196.98. The lowest was 49.49. And the median was 92.93.

NVAX's Days Sales Outstanding is ranked worse than
68.69% of 888 companies
in the Biotechnology industry
Industry Median: 72.335 vs NVAX: 106.43

Novavax's Days Sales Outstanding increased from Dec. 2022 (30.76) to Dec. 2023 (75.78).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Novavax Days Sales Outstanding Historical Data

The historical data trend for Novavax's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

146.69

2,196.98

662.28

61.33

124.52

Novavax Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																30.76	-	54.58	1,072.28	75.78

Competitive Comparison

For the Biotechnology subindustry, Novavax's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novavax Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Novavax's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Novavax's Days Sales Outstanding falls into.

Novavax Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Novavax's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (82.375	+	297.24)	/	2 )	/	556.382	*	365
=	189.8075					/	556.382	*	365
=	124.52

Novavax's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (123.657	+	297.24)	/	2 )	/	253.399	*	365 / 4
=	210.4485					/	253.399	*	365 / 4
=	75.78

Novavax (NAS:NVAX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Novavax Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Novavax's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax (Novavax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

NVAX:Mexico NVV1:Germany

Address

21 Firstfield Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Executives

Filip Dubovsky	officer: President, R&D	C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn	officer: President, R&D	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara	officer: EVP, Chief Strategy Officer	333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs	director, officer: President and CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
James F Young	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Herrmann John A Iii	officer: SVP, General Counsel	C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck	director, officer: President and CEO	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino	officer: SVP, CBO and CFO	9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly	officer: EVP, CFO and Treasurer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans	director	1048 TEXAN TRAIL, GRAPEVINE TX 76051
Rachel K. King	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Mcmanus Michael A Jr	director	241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100